Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression

BackgroundThe involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies. There are epidemiological data from subjects using NSAIDs, and experimental evidence supporting the hypothesis of prostaglandins (PGs) as regulators of tumourigenesis in the ovary. One of the end products of PG-synthesis, PGE2, regulates several key-processes, which are characteristic for tumour growth, e.g. angiogenesis, proliferation and apoptosisis. The present study investigated the pathway for PGE2 – synthesis and signalling in ovarian tumourigenesis by analysing specimen from normal ovaries (n = 18), benign (B) (n = 8), borderline type (BL) (n = 6) and malignant tumours (AC) (n = 22). The expression and cell-specific localization of COX-1, COX-2, microsomal prostaglandin E synthase-1 (mPGES-1) and two of the receptors for PGE2, EP1 and EP2, were examined by immunoblotting (IB) and immunohistochemistry (IHC).ResultsThe results are in line with earlier studies demonstrating an increase of COX-2 in AC compared to the normal ovary, B and BL tumours. Increased expressions were also observed for COX-1, mPGES-1 and EP-1 which all were significantly (p < 0.05) augmented in less differentiated AC (grades: moderately-, poorly- and undifferentiated). The increase of COX-2 was also correlated to stage (FIGO classification) with significant elevations in stages II and III. EP1 was increased in stage III while no significant alterations were demonstrated for COX-1, mPGES-1 or EP2 for stage. IHC revealed staining of the tumour cells, but also increase of COX-1, COX-2, mPGES-1 and EP1–2 in the stromal compartment of AC (grades: moderately-, poorly- and undifferentiated). This observation suggests interactions between tumour cells and stromal cells (fibroblasts, immune cells), e.g. paracrine signalling mediated by growth factors, cytokines and possibly PGs.ConclusionThe increases of COX-1, COX-2, mPGES-1 and EP1–2 in epithelial ovarian cancer, supports the hypothesis that PGE2-synthesis and signalling are of importance for malignant transformation and progression. The observed augmentations of COX-1, COX-2 and mPGES-1 have implications for future therapeutic strategies.

[1]  A. Munkarah,et al.  The effect of cyclooxygenase‐2 expression on tumor vascularity in advanced stage ovarian serous carcinoma , 2003, Cancer.

[2]  J. Morrow,et al.  Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. , 2005, Cancer research.

[3]  S. Enerbäck,et al.  The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPβ during epithelial tumour progression , 1999, British Journal of Cancer.

[4]  S. Nilsson,et al.  Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies , 2004, Acta obstetricia et gynecologica Scandinavica.

[5]  A. Godwin,et al.  Loss of TNF-α-regulated COX-2 expression in ovarian cancer cells , 2005, Oncogene.

[6]  S. Bulun,et al.  Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. , 2001, Cancer research.

[7]  R. Ozols,et al.  Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies , 2003, Cancer.

[8]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[9]  H. Hollema,et al.  Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. , 2001, Cancer research.

[10]  T. Jacks,et al.  Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. , 2006, Cancer research.

[11]  S. Enerbäck,et al.  E‐cadherin expression in human epithelial ovarian cancer and normal ovary , 1997, International journal of cancer.

[12]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[13]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[14]  Hani Doss,et al.  Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). , 2005, Oncology reports.

[15]  Makoto Murakami,et al.  Prostaglandin E synthase: a novel drug target for inflammation and cancer. , 2006, Current pharmaceutical design.

[16]  Lei-Chin Chen,et al.  Functional role of NF-IL6β and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene , 2006, Nucleic acids research.

[17]  N. Maggiano,et al.  Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  M. Brännström,et al.  Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours , 2006, International journal of cancer.

[19]  Raymond N DuBois,et al.  Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. , 2003, Cancer research.

[20]  V. Boddi,et al.  COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates. , 2004, Oncology reports.

[21]  D. Curiel,et al.  Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  A. Fürstenberg,et al.  Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference , 2003, Oncogene.

[23]  Jeannette Bigler,et al.  Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.

[24]  J. Sirois,et al.  Expression of Prostaglandin G/H Synthase Type 1, but not Type 2, in Human Ovarian Adenocarcinomas , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  O. Ishiko,et al.  Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. , 2001, International journal of molecular medicine.

[26]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[27]  P. Heinonen,et al.  Prostaglandin and thromboxane production in ovarian cancer tissue. , 1984, Gynecologic and obstetric investigation.

[28]  G. Saed,et al.  Effects of Prostaglandin E2 on Proliferation and Apoptosis of Epithelial Ovarian Cancer Cells , 2002, The Journal of the Society for Gynecologic Investigation: JSGI.

[29]  K. Wakabayashi,et al.  COX-2 and prostanoid receptors: good targets for chemoprevention. , 2002, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[30]  Yuko Kino,et al.  Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[31]  M. Morgan,et al.  Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. , 2000, Epidemiology.

[32]  A. Bergh,et al.  Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer , 2005, Clinical Cancer Research.

[33]  K. Sundfeldt,et al.  E-cadherin-catenin complex in the rat ovary: cell-specific expression during folliculogenesis and luteal formation. , 2000, Journal of reproduction and fertility.

[34]  M. Stack,et al.  Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. , 2005, Cancer research.

[35]  C. Denkert,et al.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. , 2002, The American journal of pathology.

[36]  S. Narumiya,et al.  Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.

[38]  G. Saed,et al.  Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. , 2002, Journal of the Society for Gynecologic Investigation.

[39]  S. Nordling,et al.  Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. , 2001, The American journal of pathology.

[40]  C. Haglund,et al.  Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma , 2004, Clinical Cancer Research.

[41]  S. Bandyopadhyay,et al.  Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. , 2005, American journal of obstetrics and gynecology.

[42]  S. Ochsner,et al.  Ovulation: new dimensions and new regulators of the inflammatory-like response. , 2002, Annual review of physiology.

[43]  Gynecologica Scandinavica,et al.  in ovarian carcinomas , 2000 .

[44]  P. Carlsson,et al.  Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β , 2003, British Journal of Cancer.

[45]  A. Mcneilly,et al.  Anti-inflammatory and proliferative responses in human and ovine ovarian surface epithelial cells. , 2004, Reproduction.

[46]  O. Ylikorkala,et al.  Prostacyclin and thromboxane in ovarian cancer: effect of cytostatics and prostaglandin synthesis inhibitors. , 1983, Gynecologic oncology.

[47]  M. Brännström,et al.  Leukocyte networks and ovulation. , 2002, Journal of reproductive immunology.

[48]  S. Langdon,et al.  Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas , 2005, British Journal of Cancer.

[49]  Makoto Murakami,et al.  Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. , 2004, Progress in lipid research.

[50]  W. Grizzle,et al.  Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  Fathalla Mf.  Incessant ovulation--a factor in ovarian neoplasia? [letter] , 1971 .

[52]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[53]  園下 将大.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc[Δ716] knockout mice , 2004 .

[54]  T. Bauknecht,et al.  Formation of prostaglandins by ovarian carcinomas. , 1985, Prostaglandins.

[55]  B. Davis,et al.  Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. , 2004, Gynecologic oncology.

[56]  F. Spinella,et al.  Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells , 2004, Clinical Cancer Research.